TY - JOUR T1 - Electrocardiographic Abnormalities and Troponin Elevation in COVID-19 JF - medRxiv DO - 10.1101/2020.11.12.20230565 SP - 2020.11.12.20230565 AU - Ehud Chorin AU - Matthew Dai AU - Edward Kogan AU - Lalit Wadhwani AU - Eric Shulman AU - Charles Nadeau-Routhier AU - Robert Knotts AU - Roi Bar-Cohen AU - Chirag Barbhaiya AU - Anthony Aizer AU - Douglas Holmes AU - Scott Bernstein AU - Michael Spinelli AU - David Park AU - Larry Chinitz AU - Lior Jankelson Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/16/2020.11.12.20230565.abstract N2 - Background the COVID19 pandemic has resulted in worldwide morbidity at unprecedented scale. Troponin elevation is a frequent laboratory finding in hospitalized patients with the disease, and may reflect direct vascular injury or nonspecific supply-demand imbalance. In this work, we assessed the correlation between different ranges of Troponin elevation, Electrocardiographic (ECG) abnormalities and mortality.Methods We retrospectively studied 204 consecutive patients hospitalized at NYU Langone Health with COVID19. Serial ECG tracings were evaluated in conjunction with laboratory data including Troponin. Mortality was analyzed in respect to the degree of Troponin elevation and the presence of ECG changes including ST elevation, ST depression or T wave inversion.Results Mortality increased in parallel with increase in Troponin elevation groups and reached 60% when Troponin was >1 ng/ml. In patients with mild Troponin rise (0.05 – 1.00 ng/ml) the presence of ECG abnormality resulted in significantly greater mortality.Conclusion ECG repolarization abnormalities may represent a marker of clinical severity in patients with mild elevation in Troponin values. This finding can be used to enhance risk stratification in patients hospitalized with COVID19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NYU Langone IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesreview of request will be performed ER -